琥珀酸美托洛尔、酒石酸美托洛尔治疗慢性阻塞性肺疾病伴慢性心衰的临床价值

Clinical value of metoprolol succinate and metoprolol tartrate in the treatment of chronic obstructive pulmonary disease complicated with chronic heart failure

目的探讨琥珀酸美托洛尔、酒石酸美托洛尔治疗慢性阻塞性肺疾病(简称慢阻肺)伴慢性心衰的临床价值。方法将我院70例慢阻肺伴慢性心衰患者按随机数字表法分为A组和B组,各35例。A组患者采用琥珀酸美托洛尔治疗,B组患者采用酒石酸美托洛尔治疗。比较两组患者的肺功能指标及心功能指标、生活质量评分、不良反应发生情况及6个月内再入院率。结果治疗后,两组患者的FEV1%、FEV1/FVC、LVESD、LVEDD及LVEF均改善,且A组优于B组(P<0.05)。治疗后,两组患者的呼吸症状、活动能力及疾病影响评分均降低,且A组低于B组(P<0.05)。两组患者的不良反应总发生比较,差异无统计学意义(P>0.05)。A组6个月内再入院率低于B组(P<0.05)。结论与酒石酸美托洛尔相比,对慢阻肺伴慢性心衰患者采取琥珀酸美托洛尔治疗,患者的心功能改善程度更高,生活质量改善更明显,且安全性更高,值得临床推广应用。

Objective To investigate the clinical value of metoprolol succinate and metoprolol tartrate in the treatment of chronic obstructive pulmonary disease complicated with chronic heart failure.Methods Seventy patients with chronic obstructive pulmonary disease and chronic heart failure in our hospital were randomly divided into group A and group B,with 35 cases in each group.The group A was treated with metoprolol succinate,and the group B with metoprolol tartrate.The cardiac pulmonary function indexes,function indexes,quality of life scores,adverse reactions and re-admission rate within 6 months were compared between the two groups.Results After treatment,the FEV1%,FEV1/FVC,LVESD,LVEDD and LVEF improved in both groups,and those of the group A were better than the group B(P<0.05).After treatment,the scores of respiratory symptoms,activity and disease impact of both groups decreased,and those of the group A were lower than the group B(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).The re-admission rate in the group A was lower than that in the group B(P<0.05).Conclusion Compared with metoprolol tartrate,metoprolol succinate is more effective in improving cardiac function,quality of life and safety in patients with chronic obstructive pulmonary disease and chronic heart failure,which is worthy of clinical promotion and application.